Current Report Filing (8-k)
August 05 2020 - 7:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
Form
8-K
_____________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event Reported):
August 5, 2020
HARVARD BIOSCIENCE, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware
|
001-33957
|
04-3306140
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification Number)
|
84 October Hill Road, Holliston, MA 01746
|
(Address of Principal Executive Offices) (Zip Code)
|
(508) 893-8999
(Registrant's telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
[ ]
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
[ ]
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
[ ]
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
[ ]
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.01 par value
|
HBIO
|
The NASDAQ Stock Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 2.02.
|
Results of Operations and Financial Condition.
|
On August 5, 2020, Harvard Bioscience, Inc. (the “Company”)
issued a press release announcing financial results for the three and six months ended June 30, 2020 and the details of a related
conference call to be held at 8:00 AM EST on August 5, 2020. The press release is furnished as Exhibit 99.1 and incorporated herein
by reference.
The information in Item 2.02 of this Current Report on Form
8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific
reference in such a filing.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
HARVARD BIOSCIENCE, INC.
|
|
|
|
|
|
|
Date: August 5, 2020
|
By:
|
/s/ James Green
|
|
|
James Green
|
|
|
Chief Executive Officer
|
|
|
|
Harvard Bioscience (NASDAQ:HBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Harvard Bioscience (NASDAQ:HBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024